Compare Tripadvisor Inc Common Stock (TRIP) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Tripadvisor Inc Common Stock vs 10X Genomics Inc — how do they compare? Tripadvisor Inc Common Stock trades at $11.04 (market cap $1.26B), while 10X Genomics Inc trades at $58.6 (market cap $7.64B). The key difference: 10X Genomics Inc is far larger — about 6.1× Tripadvisor Inc Common Stock's market cap, and 10X Genomics Inc is trading nearer its 52-week high, Tripadvisor Inc Common Stock nearer its low. Which is the better fit depends on your goals.
| TRIP | TXG | |
|---|---|---|
Market Cap | $1.26B | $7.64B |
Sector | Consumer Cyclical | Health |
52-Week High | $19.14 | $58.57 |
52-Week Low | $9.24 | $11.34 |
Enterprise Value | $1.31B | $7.17B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Tripadvisor (TRIP) trades at $10.78, up 3.45% today, but faces bearish technical signals with recent earnings misses. The company maintains strong gross margins at 92.11% but struggles with thin net income margins of 0.27%. Recent Q2 2026 results missed expectations, though the $700M sale of TheFork to American Express provides strategic focus and cash infusion. Analyst consensus is mixed with 62.5% hold ratings and a $13.71 price target suggesting 27% upside potential from current levels.
TRIP presents a turnaround opportunity with simplified operations post-TheFork sale and Viator's growth potential, but faces persistent search-related pressures and uneven travel demand. The stock trades at reasonable valuations (P/S 0.7x) but carries execution risks amid competitive threats. Cash flow trends show volatility, with negative net cash flow projected for 2026, requiring careful monitoring of the company's strategic execution.
TXG is trading at $52.03, up 14.1% in the past 24 hours, reflecting strong momentum. The stock exhibits a bullish technical signal with moving averages supporting upward trends, while RSI levels suggest mild overbought conditions. Fundamentally, the company reported Q2 2026 revenue of $151 million, beating estimates, and has shown consistent earnings beats in recent quarters. Recent news highlights collaborations with Cleveland Clinic and the acquisition of Proteintech Genomics, expanding its multiomics capabilities and reinforcing growth prospects.
The outlook for TXG is cautiously optimistic, driven by earnings outperformance and strategic expansions, but risks include persistent net losses and high valuation multiples. Analyst consensus is mixed with a $46 price target, indicating potential downside from current levels. Investors should weigh revenue growth against profitability challenges and monitor execution on new initiatives for sustained upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Tripadvisor Inc Common Stock
TripAdvisor is the world's leading travel metasearch company. The website offers 1 billion reviews and information on about 8 million accommodations, restaurants, experiences, airlines, and cruises. In 2021, 74% of revenue came from the company's core segment, which includes hotel revenue generated through advertising on its metasearch platform. Viator, its experiences brand, was 20% of sales in 2021, and TheFork, its dining brand, represented 9% of revenue (about 3% of sales were intersegment, which are eliminated from consolidated revenue).
Read more on TRIP →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
